AgomAb
A biotech company pioneering therapies that modulate regenerative pathways to achieve structural tissue repair and functional organ recovery.
Its growing pipeline of highly specific monoclonal antibodies is designed to treat a range of acute and chronic conditions that involve inflammatory, metabolic and fibrotic processes.
By combining new scientific insights with robust development expertise, the Belgium-based company claims to be building a company to lead to the emergence of truly regenerative medicines.
Latest AgomAb News & Features
29 November 2023
11 October 2023
4 November 2021
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze